Drug intelligence / Profile preview

tetanus toxoid (GSK)

Development stage
Approved
Lead developer
Sanofi Pasteur
Modality
Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Tetanus toxoid is a formaldehyde-inactivated toxin (toxoid) derived from the bacterium *Clostridium tetani*. It is used to induce active immunity against tetanus (lockjaw) by stimulating the production of specific IgG antitoxins that neutralize the native tetanus toxin. The toxoid is typically adsorbed onto aluminum salts, such as aluminum hydroxide or aluminum phosphate, to enhance its immunogenicity. While it can be administered as a standalone vaccine for booster doses, it is most commonly found as a core component of various combination vaccines, including DTaP (diphtheria, tetanus, and acellular pertussis), Tdap, and pediatric hexavalent vaccines like Pediarix and Vaxelis. It is a fundamental part of standard pediatric and adult immunization schedules worldwide.

Brand names
Tetanus Toxoid Adsorbed
Other names
Clostridium tetani toxoidTetanus vaccineTetanus toxoid (formaldehyde inactivated)Clostridium tetani toxoid antigen (formaldehyde inactivated)

Beyond the preview

Go deeper on tetanus toxoid (GSK).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tetanus toxoid (GSK).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call